Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2012

Open Access 01-12-2012 | Primary research

Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in Vitro and in Vivo

Authors: Zhi-Jun Dai, Xiao-Bin Ma, Hua-Feng Kang, Jie Gao, Wei-Li Min, Hai-Tao Guan, Yan Diao, Wang-Feng Lu, Xi-Jing Wang

Published in: Cancer Cell International | Issue 1/2012

Login to get access

Abstract

Background

Cyclooxygenase-2(COX-2) promotes carcinogenesis, tumor proliferation, angiogenesis, prevention of apoptosis, and immunosuppression. Meanwhile, COX-2 over-expression has been associated with tumor behavior and prognosis in several cancers. This study investigated the antitumor effects of the selective COX-2 inhibitor, Celecoxib, on breast cancer in vitro and in vivo.

Methods

Human breast cancer MCF-7 and MDA-MB-231 cells were cultured with different concentration (10, 20, 40 μmol/L) of celecoxib after 0-96 hours in vitro. MTT assay was used to determine the growth inhibition of breast cancer cells in vitro. The expression of COX-2 on mRNA was measured by real-time quantitive PCR analysis. Flow cytometry was performed to analyze the cell cycle of MCF-7 cells. Levels of PGE2 were measured by ELISA method. The in vivo therapeutic effects of celecoxib were determined using rat breast cancer chemically induced by 7,12-dimethylben anthracene (DMBA).

Results

The inhibition of proliferation of both MCF-7 and MDA-MB-231 cells in vitro by celecoxib was observerd in time and dose dependent manner. Celecoxib effectively down-regulated the expression of COX-2. The cell cycle was arrested at G0/G1, and rate of cells in S phase was obviously decreased. Levels of PGE2 were inhibited by Celecoxib. The tumor incidence rate of the celecoxib group was lower than that of the control group. In addition, the tumor latency period of the celecoxib group was longer than that of the control group.

Conclusions

Celecoxib inhibited the proliferation of breast cancer cell lines in vitro, and prevented the occurrence of rat breast cancer chemically induced by DMBA. Therefore, celecoxib exhibits an antitumor activity and seems to be effective in anti-tumor therapy.
Appendix
Available only for authorised users
Literature
1.
Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, Dubois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998, 93: 705-716. 10.1016/S0092-8674(00)81433-6.CrossRefPubMed
2.
Gately S: The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev. 2000, 19: 19-27. 10.1023/A:1026575610124.CrossRefPubMed
3.
Sheng H, Shao J, Morrow JD, Beauchamp RD, Dubois RN: Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998, 58: 362-366.PubMed
4.
Tsujii M, Kawano S, DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA. 1997, 94: 3336-3340. 10.1073/pnas.94.7.3336.PubMedCentralCrossRefPubMed
5.
Koki AT, Masferrer JL: Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control. 2002, 9: 28-35.PubMed
6.
Choy H, Milas L: Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance?. J Natl Cancer Inst. 2003, 95: 1440-1452. 10.1093/jnci/djg058.CrossRefPubMed
7.
Kobayashi H, Gonda T, Uetake H, Higuchi T, Enomoto M, Sugihara K: JTE-522, a selective COX-2 inhibitor, interferes with the growth of lung metastases from colorectal cancer in rats due to inhibition of neovascularization: a vascular cast model study. Int J Cancer. 2004, 112: 920-926. 10.1002/ijc.20523.CrossRefPubMed
8.
Lou J, Fatima N, Xiao Z, Stauffer S, Smythers G, Greenwald P, Ali IU: Proteomic profiling identifies cyclooxygenase-2-independent global proteomic changes by celecoxib in colorectal cancer cells. Cancer Epidemiol Biomarkers Prev. 2006, 15: 1598-1606. 10.1158/1055-9965.EPI-06-0216.CrossRefPubMed
9.
Abou-Issa HM, Alshafie GA, Seibert K, Koki AT, Masferrer JL, Harris RE: Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis. Anticancer Res. 2001, 21: 3425-3432.PubMed
10.
Park W, Oh TY, Han JH, Pyo H: Antitumor enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing Cyclooxygenase-2. J Exp Clin Cancer Res. 2008, 27: 66-74. 10.1186/1756-9966-27-66.PubMedCentralCrossRefPubMed
11.
Müller-Decker K, Fürstenberger G: The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis. Mol Carcinog. 2007, 46: 705-710. 10.1002/mc.20326.CrossRefPubMed
12.
Grösch S, Maier TJ, Schiffmann S, Geisslinger G: Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst. 2006, 98: 736-747. 10.1093/jnci/djj206.CrossRefPubMed
13.
Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, Seibert K, Rao CV: Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 2000, 60: 293-297.PubMed
14.
Jang TJ, Jung HG, Jung KH, O MK: Chemopreventive effect of celecoxib and expression of cyclooxygenase-1 and cyclooxygenase-2 on chemically-induced rat mammary tumours. Int J Exp Pathol. 2002, 83: 173-182. 10.1046/j.1365-2613.2002.00228.x.PubMedCentralCrossRefPubMed
15.
Keller JJ, Giardiello FM: Chemoprevention strategies using NSAIDs and COX-2 inhibitors. Cancer Biol Ther. 2003, 2: 1-9.CrossRef
16.
Hilmi I, Goh KL: Chemoprevention of colorectal cancer with nonsteroidal anti-inflammatory drugs. Chin J Dig Dis. 2006, 7: 1-6. 10.1111/j.1443-9573.2006.00236.x.CrossRefPubMed
17.
Dai ZJ, Gao J, Li ZF, Ji ZZ, Kang HF, Guan HT, Diao Y, Wang BF, Wang XJ: In Vitro and In Vivo Antitumor Activity of Scutellaria barbate Extract on Murine Liver Cancer. Molecules. 2011, 16: 4389-4400. 10.3390/molecules16064389.CrossRefPubMed
18.
Zhang JQ, Li YM, Liu T, He WT, Chen YT, Chen XH, Li X, Zhou WC, Yi JF, Ren ZJ: Antitumor effect of matrine in human hepatoma G2 cells by inducing apoptosis and autophagy. World J Gastroenterol. 2010, 16: 4281-4290. 10.3748/wjg.v16.i34.4281.PubMedCentralCrossRefPubMed
19.
Tai MH, Weng CH, Mon DP, Hu CY, Wu MH: Ultraviolet C Irradiation Induces Different Expression of Cyclooxygenase 2 in NIH 3T3 Cells and A431 Cells: The Roles of COX-2 Are Different in Various Cell Lines. Int J Mol Sci. 2012, 13: 4351-4366. 10.3390/ijms13044351.PubMedCentralCrossRefPubMed
20.
Whitsett T, Carpenter M, Lamartiniere CA: Resveratrol, but not EGCG, in the diet suppresses DMBA-induced mammary cancer in rats. J Carcinog. 2006, 5: 15-10.1186/1477-3163-5-15.PubMedCentralCrossRefPubMed
21.
Nakatsugi S, Ohta T, Kawamori T, Mutoh M, Tanigawa T, Watanabe K, Sugie S, Sugimura T, Wakabayashi K: Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6 -phenylimidazo[4,5-b]pyridine (PhIP)- induced mammary gland carcinogenesis in rats. Jpn J Cancer Res. 2000, 91: 886-892. 10.1111/j.1349-7006.2000.tb01030.x.CrossRefPubMed
22.
Russo J, Russo IH: Atlas and histologic classification of tumors of the rat mammary gland. J Mammary Gland Biol Neoplasia. 2000, 5: 187-200. 10.1023/A:1026443305758.CrossRefPubMed
23.
Barnes NL, Flint PJ, Knox WF, Clarke RB, Bundred NJ: Celecoxib decreases COX-2 protein expression and increases apoptosis in ductal carcinoma in situ of the breast in vivo. Meeting Abstracts: AACR. 2005, 532-
24.
Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P: Celecoxib, a selective COX-2 inhibitor, induces apoptosis and reduces VEGF levels in a preclinical model of metastatic breast cancer. 2004, Meeting Abstracts: AACR, 317-
25.
Ding H, Han C, Zhu J, Chen CS, D'Ambrosio SM: Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. Int J Cancer. 2005, 113: 803-810. 10.1002/ijc.20639.CrossRefPubMed
26.
Susan LJ, Sheldon M, John F, Kathleen G, Constantine D, Masferrer JL, Ben SZ, Harjeet S, Irma HR: The Cyclooxygenase-2 Inhibitor, Celecoxib, Prevents the Development of Mammary Tumors in HER-2/neu Mice. Cancer Epidemiol Biomarkers Prev. 2003, 12: 1486-1491.
27.
Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, Thaler HT, Muller WJ, Du B, Brown AM, Dannenberg AJ: Celecoxib, a Selective Cyclooxygenase 2 Inhibitor, Protects against Human Epidermal Growth Factor Receptor 2 (HER-2)/ neu-induced Breast Cancer. Cancer Res. 2002, 62: 5405-5407.PubMed
28.
Rasmuson A, Kock A, Fuskevåg OM, Kruspig B, Simón-Santamaría J, Gogvadze V, Johnsen JI, Kogner P, Sveinbjörnsson B: Autocrine prostaglandin E2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma. PLoS One. 2012, 7: e29331-10.1371/journal.pone.0029331.PubMedCentralCrossRefPubMed
29.
Pockaj BA, Basu GD, Pathangey LB, Gray RJ, Hernandez JL, Gendler SJ, Mukherjee P: Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol. 2004, 11: 328-339. 10.1245/ASO.2004.05.027.CrossRefPubMed
30.
Tari AM, Simeone AM, Li YJ, Gutierrez-Puente Y, Lai S, Symmans WF: Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl) retinamide inhibitory effects in breast cancer cells. Lab Invest. 2005, 85: 1357-1367. 10.1038/labinvest.3700339.CrossRefPubMed
31.
Shin YK, Park JS, Kim HS, Jun HJ, Kim GE, Suh CO, Yun YS, Pyo H: Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res. 2005, 65: 9501-9509. 10.1158/0008-5472.CAN-05-0220.CrossRefPubMed
32.
Dvory-Sobol H, Cohen-Noyman E, Kazanov D, Figer A, Birkenfeld S, Madar-Shapiro L, Benamouzig R, Arber N: Celecoxib leads to G2/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner. Eur J Cancer. 2006, 42: 422-426. 10.1016/j.ejca.2005.11.009.CrossRefPubMed
33.
Liu DB, Hu GY, Long GX, Qiu H, Mei Q, Hu GQ: Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation. Acta Pharmacol Sin. 2012, 33: 682-690. 10.1038/aps.2012.18.PubMedCentralCrossRefPubMed
34.
Márquez-Rosado L, Trejo-Solís MC, García-Cuéllar CM, Villa-Treviño S: Celecoxib, a cyclooxygenase-2 inhibitor, prevents induction of liver preneoplastic lesions in rats. J Hepatol. 2005, 43: 653-660. 10.1016/j.jhep.2005.02.032.CrossRefPubMed
35.
Li WZ, Wang XY, Li ZG, Zhang JH, Ding YQ: Celecoxib enhances the inhibitory effect of cisplatin on Tca8113 cells in human tongue squamous cell carcinoma in vivo and in vitro. J Oral Pathol Med. 2010, 39: 579-584.PubMed
Metadata
Title
Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in Vitro and in Vivo
Authors
Zhi-Jun Dai
Xiao-Bin Ma
Hua-Feng Kang
Jie Gao
Wei-Li Min
Hai-Tao Guan
Yan Diao
Wang-Feng Lu
Xi-Jing Wang
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2012
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-12-53

Other articles of this Issue 1/2012

Cancer Cell International 1/2012 Go to the issue

Editorial

Granulocyte-macrophage stimulating factor (GM-CSF) increases circulating dendritic cells but does not abrogate suppression of adaptive cellular immunity in patients with metastatic colorectal cancer receiving chemotherapy

Primary research

Toxicities effects of pharmaceutical, olive mill and textile wastewaters before and after degradation by Pseudomonas putida mt-2

Primary research

Cycloartane-3,24,25-triol inhibits MRCKα kinase and demonstrates promising anti prostate cancer activity in vitro

Primary research

Molecular network profiling of U373MG human glioblastoma cells following induction of apoptosis by novel marine-derived anti-cancer 1,2,3,4-tetrahydroisoquinoline alkaloids

Primary research

Modulation of doxorubicin cytotoxicity by resveratrol in a human breast cancer cell line

Primary research

Effect of lycopene on cell viability and cell cycle progression in human cancer cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits